Non-Small Cell Lung Cancer Market

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 500K cases in the 7MM were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year. Analysis indicates that the most common ge...

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. the total number of incident cases of NSCLC across the 7MM was approximately 500,000 in 2022 and is projected to reach around 600,000 cases by 2032. Studies show that non-small cell lung cancer aff...

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Nov 29, 2024

According to the World Health Organization (WHO), in 2022, there were approximately 2.5 million new cases of lung cancer globally, which accounted for 12.4% of all newly diagnosed cancer cases. Lung cancer continues to be one of the most common and deadly malignancies worldwide, with significant contributions to gl...

Sep 08, 2023

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Nov 25, 2022

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

Aug 23, 2019

The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...